mTOR inhibitors in cancer therapy

被引：261

作者：

Zaytseva, Yekaterina Y. ^{[1
]}

Valentino, Joseph D. ^{[1
,2
]}

Gulhati, Pat ^{[3
]}

Evers, B. Mark ^{[1
,2
]}

机构：

[1] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA

[2] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA

[3] Univ Texas Med Branch, MD PhD Program, Galveston, TX USA

来源：

CANCER LETTERS | 2012年 / 319卷 / 01期

关键词：

mTOR; Cancer; Cancer therapy; Drug resistance; DUAL PI3K/MTOR INHIBITOR; MAMMALIAN TARGET; CELL MOTILITY; COMPLEX; GROWTH; ACTIVATION; PROLIFERATION; PATHWAY; PHOSPHORYLATION; RICTOR;

D O I：

10.1016/j.canlet.2012.01.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer. (c) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 7

页数：7

共 61 条

[1]

Abraham R.T., 2009, SEMIN ONCOL, V36, P3, DOI 10.1053/j.seminoncol.2009.10.011

[2] Clinical activity of mammalian target of rapamycin inhibitors in solid tumors [J].

Alvarado, Yesid ;

Mita, Monica M. ;

Vemulapalli, Sushma ;

Mahalingam, Devalingam ;

Mita, Alain C. .

TARGETED ONCOLOGY, 2011, 6 (02) :69-94

[3] Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors [J].

Capdevila, Jaume ;

Salazar, Ramon ;

Halperin, Irene ;

Abad, Albert ;

Yao, James C. .

CANCER AND METASTASIS REVIEWS, 2011, 30 (01) :27-34

[4]

Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]

[5] Targeting the mTOR signaling network in cancer [J].

Chiang, Gary G. ;

Abraham, Robert T. .

TRENDS IN MOLECULAR MEDICINE, 2007, 13 (10) :433-442

[6] Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation [J].

Choo, Andrew Y. ;

Yoon, Sang-Oh ;

Kim, Sang Gyun ;

Roux, Philippe P. ;

Blenis, John .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (45) :17414-17419

[7] Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake [J].

Edinger, AL ;

Thompson, CB .

MOLECULAR BIOLOGY OF THE CELL, 2002, 13 (07) :2276-2288

[8] mTOR and cancer: many loops in one pathway [J].

Efeyan, Alejo ;

Sabatini, David M. .

CURRENT OPINION IN CELL BIOLOGY, 2010, 22 (02) :169-176

[9] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers [J].

Engelman, Jeffrey A. ;

Chen, Liang ;

Tan, Xiaohong ;

Crosby, Katherine ;

Guimaraes, Alexander R. ;

Upadhyay, Rabi ;

Maira, Michel ;

McNamara, Kate ;

Perera, Samanthi A. ;

Song, Youngchul ;

Chirieac, Lucian R. ;

Kaur, Ramneet ;

Lightbown, Angela ;

Simendinger, Jessica ;

Li, Timothy ;

Padera, Robert F. ;

Garcia-Echeverria, Carlos ;

Weissleder, Ralph ;

Mahmood, Umar ;

Cantley, Lewis C. ;

Wong, Kwok-Kin .

NATURE MEDICINE, 2008, 14 (12) :1351-1356

[10] Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony [J].

Foster, Kathryn G. ;

Fingar, Diane C. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (19) :14071-14077

← 1 2 3 4 5 6 7 →